Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus THEOPHYL 225.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus THEOPHYL 225.
AEROLATE III vs THEOPHYL-225
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/mL.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Category C
Category C
Bronchodilator
Bronchodilator